Set for hypogalactia prevention in women with thyroid diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a set for hypogalactia prevention in women with thyroid diseases. The set for hypogalactia prevention in women with thyroid diseases which includes the preparations: aminophylline; no-spa; a preparation improving blood rheology specified in the group: rheopolyglucinum, fresh frozen plasma, a microdose of aspirin; an energy preparation specified in the group: glucose, actovegin; amino acid specified in the group: methionine, glutamic acid, galascorbinum; antioxidants, a ferriferous preparation specified in the group: Sorbifer Durules, tardiferon; and a vitamin complex containing vitamins A, E, C.

EFFECT: set reduces rate and severity of lactation disorders in women with a thyroid pathology and improves breast milk quality.

2 cl

 

The invention relates to the field of pharmaceutical industry, namely the creation of medicines-sets for the prevention of hypogalactia in women with thyroid disease.

With the peculiarities of pregnancy and birth is closely associated with the nature of the lactational function. Lactation is a complex process, the preparation of which begins with early pregnancy (Pregnancy and thyroid disease, Makhachkala, 2005). In female milk finely balanced content of nutrients, enzymes, hormones, immunity factors and other components (Lactation in women with thyroid disease in the region, endemic iodine deficiency, Makhachkala, 2005). On this basis, during the period of gestation and lactation in women with disorders of the thyroid gland (thyroid) correction and prevention of complications violations of the lactational function is the actual problem.

Lactational function in women with disorders of the thyroid gland is very little coverage of domestic and foreign researchers.

With poorer quality of life, decrease in women's health, especially during the period of gestation increased the incidence of complications lactational function. Various extragenital diseases and pathological processes, complicating pregnancy, childbirth and the postpartum period, contribute violated the Y. this function postpartum. Among all the complications of pregnancy diseases of the thyroid gland occupy a special place.

In women with complicated pregnancy children are born weak, with signs of intrauterine growth retardation and impaired postnatal adaptation. Therefore natural full breastfeeding breast milk is of particular importance, as the main therapeutic factor (who, 1989).

In recent years, according to the literature, the frequency of hypogalactia increased, it is diagnosed 26-80% of breastfeeding mothers (Bach CENTURIES, 1992; Garaeva G.R., 1992, and others)

Lactational function of the mammary gland is in particular based on the function of the thyroid gland. Thyroid cancer has a significant impact not only on the biochemical composition of the milk, but also determines the amount of secreted milk.

The present invention is to develop a comprehensive daily set of medicines for the prevention of hypogalactia in women with thyroid disease.

The technical result is manifested in the reduction of frequency and severity of violations of the lactational function in women with disorders of the thyroid gland and in the improvement of the qualitative composition of milk.

The problem is solved by a kit for the prevention of hypogalactia in women with thyroid disease, vkljuchajuwih the drugs: aminophylline; the noshpa; drugs, improves blood rheology; energy products; amino acids; antioxidants, iron supplements and vitamin complexes, containing vitamins a, E, C.

The set contains a single dose of drugs.

In addition, the set of drugs that improve blood rheology, selected from the group reopoliglyukin, fresh frozen plasma, microdose aspirin; energy drugs selected from the group of glucose, Actovegin; amino acids selected from the group of methionine, glutamic acid, glaskolben and iron supplements selected from the group sorbifer-duralex, tardyferon.

On the basis of the Republican Perinatal Centre of the Republic of Dagestan were surveyed 396 women in the period of gestation and puerperae: 100 pregnant women without pathology of the thyroid gland and 296 - with pathology of the thyroid gland (diffuse goiter, multinodular goiter, hypothyroidism, hyperthyroidism). Age of surveyed amounted 17-40 years.

A comprehensive survey of women with disorders of the thyroid gland with the calculation of relative risk factors have enabled us to predict the course of pregnancy and childbirth and to differentiate obstetric approach to resolution. Pregnant women with different pathologies of the thyroid gland were divided into groups, one of which received conventional treatment and the other is a comprehensive treatment of the declared set include what it drugs: aminophylline; the noshpa; drugs, uluchshauschie rheological properties of blood; energy products; amino acids; antioxidants, iron supplements and vitamin complexes, containing vitamins a, E, C.

Drugs, improves blood rheology, selected from the group reopoliglyukin, fresh frozen plasma, microdose aspirin; energy drugs selected from the group of glucose, Actovegin; amino acids selected from the group of methionine, glutamic acid, glaskolben and iron supplements selected from the group sorbifer-duralex, tardyferon.

The set contains a single dose of medications with dosages, regulated by the Ministry of health of the Russian Federation.

Prevention is based on the results of the study during pregnancy, childbirth and lactation function. Besides, as usual, attention was paid to correct and balanced nutrition for pregnant women and nursing mothers.

For the qualitative evaluation of milk conducted a study of the chemical composition of Mature milk on day 6 postpartum, proteins, fats, carbohydrates, amino acids, micro - and macro-elements and vitamins.

On the basis of the received results the survey was administered complex set of medicines throughout pregnancy and during lactation.

Pro is actica declared by the set provides a favorable prognosis for the mother and child.

The result of all these changes in the system mother-placenta-fetus in pregnant women with thyroid pathology was significant change in the pregnancy, birth, and the condition of the newborn. Decreased the number of complications.

The analysis of the obtained levels of steroid hormones under the influence of complex treatment of a set of significant difference from those in the group of pregnant women not receiving this therapy. Thus, increased 2 or more times the content in plasma estriol, which reflects the functional state of the fetoplacental system and intrauterine fetus.

The levels of placental lactogenic and prolactin in serum in the group who received integrated treatment set, significantly higher than after conventional treatment.

Among newborns from mothers treated with this set, hypotrophy of III degree was not observed, and in the group with abnormal thyroid gland is not treated, the average 8,24% of pregnant women were observed fetal hypotrophy of the III degree.

Prevention suggested set of drugs is possible to reduce the frequency and severity of violations of the lactational function in women with disorders of the thyroid gland by 38.6%.

Correction of disorders of the neuroendocrine regulation of the lactational function with the help of this set not only contributes to the normalization of lactogenesis and lactamase, but also to improve quality with the composition of milk, increased content of proteins, fats, carbohydrates and vitamins. Fruit weight in newborns from mothers treated set, of 267.8 g more than in the group not receiving the drugs in the set.

1. Set to prevent hypogalactia in women with thyroid disease include medications: aminophylline; noshpa; a drug that improves blood rheology, selected from the group reopoliglyukin, fresh frozen plasma, microdose aspirin; energy drug selected from the group of glucose, Actovegin; amino acid selected from the group of methionine, glutamic acid, glaskolben; antioxidants, iron preparation selected from the group: sorbifer-duralex, tardyferon; and vitamin complex, containing vitamins a, E, C.

2. The kit according to claim 1 contains a single dose of drugs.



 

Same patents:

FIELD: medicine.

SUBSTANCE: said preparation contains the components as follows, %: Lincomycin hydrochloride 2.0-4.0; Dioxidine 0.5-1.0; soft Monoglyceride 3.0; distilled Monoglyceride 3.0; Vaseline oil to 100. The preparation is applied to treat all forms of mastitis in lactating period. Prior to introduction thereof, udder secretion is milked dry from an affected portion and utilised; a dug is disinfected. Before use, the contents of a syrette or a bottle is heated up to 37C, agitated thoroughly to a uniform suspension, a sterile syringe is filled with 10 ml thereof from the bottle. The syringe or the syrette is tightly pressed to outer orifice of teat canal. The preparation is introduced therein by careful pressing the syringe piston. After introduction, gentle massage of the affected dug follows bottom-up. Considering the severity of inflammatory process, the preparation is introduced in a dose 10 ml once a day (preferentially, after afternoon milking) every 24 hours to ensure complete recovery of the affected dug portion. (2-4 times).

EFFECT: improved therapeutic effectiveness.

9 tbl, 5 ex

FIELD: agriculture; veterinary science.

SUBSTANCE: application of cysteamine, its salt or composition, containing cysteamine or its salt, stabilizer and/or coated carrier to improve lactation of the milking animals, particularly cows.

EFFECT: increases milk yield, its fat and protein content.

42 cl, 24 tbl, 1 dwg

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to compounds of the general formula (I): wherein R1 represents (C1-C4)-alkyl with branched or linear chain; R2 represents hydrogen atom (H); R3 represents (C1-C4)-alkyl with branched or linear chain; R4 represents (C1-C4)-alkyl with branched or linear chain, (C2-C4)-alkenyl; R5 represents -SO2NR10R11; R8 represents (C1-C4)-alkyl with branched or linear chain; each R10 and R11 represents independently H or (C1-C12)-alkyl with branched or linear chain; or R10 and R11 in common with nitrogen atom to which they are bound form pyrrolinone group, piperidyl, morpholinyl, 4-N(R13)-piperazinyl that are substituted optionally with (C1-C4)-alkyl with branched or linear chain, -NR14R15, phenyl group substituted optionally with -OH or phenyl group bound in common with other substituted phenyl group by carbonyl group; R13 represents (C1-C4)-alkyl with branched or linear chain, (C2-C6)-alkyl with branched or linear chain and substituted with hydroxyl; (C2-C6)-alkyl with branched or linear chain substituted with phenyl; (C2-C6)-hydrocarbon with branched or linear chain substituted with -CO2R8; wherein each radical among R14 and R15 represents independently H; (C1-C4)-alkyl with branched or linear chain, or its pharmaceutically acceptable salt. The claimed compounds possess inhibitory effect on activity of phosphodiesterase-5 and can be used for production of drug for treatment or prophylaxis of diseases associated with phospholipase and its function. Also, invention relates to pharmaceutical composition, medicinal composition for veterinary science, and intermediate compounds IA-IG used for synthesis of compound of the formula (I).

EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

8 cl, 2 tbl, 4 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: veterinary science.

SUBSTANCE: one should apply liniment that contains an active substance being "Todicamp-ideal" and a vegetable foundation as a mustard-pumpkin fuse obtained while manufacturing "Volgogradskoe" vegetable oil at weight ratio of mustard and pumpkin oils being 1:9 weight portions. Moreover, "Todicamp-ideal" and mustard-pumpkin fuse are at weight ratio of 10-12 : 90-88 weight portions. In some cases of liniment application upon affected part of cow's udder should be combined with peroral intake of "Todicamp-ideal". The innovation provides simultaneous antiphlogistic, antimicrobial and immunostimulating effect.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to method of biological material disinfection. Method of removing trialkylphosphate solvent and detergent, which represents polyoxiethylene ether, from mixture of plasma, trialkylphosphate solvent and said detergent, where solvent and detergent were used for virus plasma inactivation, include treatment with synthetic hydrophobic adsorbent from polystyrene and divinylbenzole copolymer in ratio 1 g of adsorbent per 1-8 ml of plasma for 30-60 min at 20-30C, and collection of treated plasma, where both solvent and detergent are removed by one-stage processing by hydrophobic interaction.

EFFECT: invention ensures safe, efficient and economical method of removing viricidal preparations, that is solvent and detergent from virus-inactivated joined in pool plasma by means of hydrophobic interaction chromatography.

9 cl, 7 tbl, 1 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used in treatment of mammary gland cancer (MGC). Method is realised in the following way. After confirmation of malignant character of tumour tissue in patient sampling of 200 ml of blood from peripheral vein into reservoir with hemopreservative is carried out, after that it is centrifuged with separation of plasma, which is combined with cyclophosphane in amount 400 mg/m2, doxorubincin in dose 40 mg/m2 is introduced into erythrocyte mass; both reservoirs are incubated in thermostat for 30 minutes at temperature 37C. After that, sucking of blood from the place of tumour tissue sampling is carried out with further introduction into it of 200 mg of cyclophosphane diluted in 5 ml of physiological solution. Tissue of mammary gland around tumour is infiltrated with incubated plasma with cyclophosphane, and erythrocyte mass with doxorubicin is introduced intravenously by drop infusion.

EFFECT: application of the invention makes it possible to increase efficiency of MGC treatment due to creation of maximal concentration of chemical preparations in leision focus and prevention of tumour process dissemination.

1 ex

FIELD: medicine.

SUBSTANCE: autoblood plasma components are fractionated. The autoblood plasma components are exposed to anion-exchange chromatography. The components sorbed on an anion exchanger are recovered. The recovered components are lyophilised. The components are introduced in the ratio 3:1000 in a skin penetrating composition of ointment consistency. The composition is applied in the form of applications on a body surface in a projection of a zone of regenerated bone formation.

EFFECT: method allows to reduce injures and to extend indications for administration.

1 ex, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose.

EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange.

5 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to anesthesiology and resuscitation science, and can be used in necessity of anesthesia before surgery, during it and after it. For this purpose 10-15 minutes before incision 0.75% ropivacaine solution in volume 3.0-4.0 ml is introduced between spinous processes Th2-Th3 and 4.0-5.0 ml between spinous processes Th6-Th7. During narcosis anesthesia is supplemented with introduction of 3-5 mg of morphine hydrochloride solution. In resuscitation department between spinous processes Th6-Th7 0.2% ropivacaine solution is introduced at rate 4.0-6.0 ml per hour during 3-4 days, and between spinous processes Th2- Th3 0.2% ropivacaine solution is introduced in dose 3.0-4.0 ml up to three times per day during 3-4 days. Anesthesia is supplemented by introduction of 3-5 mg of morphine hydrochloride solution. After transferring patient to surgery department, anesthesia is carried out by constant introduction at the same levels of 0.2% ropivacaine solution at rate 6.0-8.0 ml per hour during 3-4 days, also introducing morphine hydrochloride solution in dose 3-5 mg per day.

EFFECT: method allows to ensure adequate anesthesia at all stages of treatment due to continuous and prolonged dosing of medications.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatocosmetology and can be used for face and neck skin rejuvenation in women. For this purpose plasmapheresis in mode of discontinuous flow separation with sampling of 800-1000 ml of blood is carried out. In course of carrying out plasmapheresis after the first cycle, native plasma is taken and immediately introduced intradermally papularly on Langer lines. Diametre of papules is 0.5-1 cm, distance between them is 1.5-2.5 cm. Total volume of introduced plasma is 5-10 ml. Course consists of 2-3 procedures after 12-16 days.

EFFECT: method allows to increase efficiency of face and neck skin rejuvenation in women due to combination of local and systemic impact of plasma, which possesses high tropism to skin cells, which ensures formation of new collagen in skin.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to dentistry. There is offered a material which contains thrombocyte-enriched patient's autoplasma, titanium nickelide powder of particle size to 100 nm, 2.5% colloidal nano-structured silver of particle size to 20 nm. There is offered a method for making a material that implies that patient's blood is centrifuged, plasma is separated from the blood clot, the separated clot is homogenised, colloidal nano-structured silver, nickelide powder and prepared centrifuged plasma are added thereto, then the components are mixed by ultrasound to produced a nacre green homogeneous composition to be used within 1-2 hours.

EFFECT: invention provides reliable implant fixation in a bone, and restoration of the bone and connective tissue.

2 cl, 2 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity.

EFFECT: method provides endotoxin weakening in the bloodstream, intertissue spaces and cavities due to combined multidirectional local and system effect on the lymphoid system.

3 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and may be used in treatment patients with breast cancer. The method includes intravenous drip-feed of antitumor chemotherapeutic agents in autoplasma. At that the received autoplasma is exposed for 30 minutes with alternating magnetic field with parametres of 100 Hz, 50 mT. Then each antitumor chemotherapeutic agent in a single dose is mixed with autoplasma and is incubated at +37.0 C for not less than 30 minutes and is reirrigated intravenously by drop infusion.

EFFECT: invention enables to reduce size of the tumor and lymph nodes, transfer patients with locally advanced process from inoperable to operable condition, achieve remission due to concentration of chemical preparations of the highest possible effectiveness, and its delivery to the target-organs with the help of the plasma exposed to the magnetic field action.

5 tbl, 4 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating the patients with advanced and recurrent skin cancer. Substance of the method consists that the patient is exposed to the discrete gravity plasmapheresis; blood 400 ml is drawn once; prepared autoplasma is divided on two portions, each 150 ml whereto 30 ml of erythromass and 10 portions, each 10 ml. All the portions are collected in sterile containers and frozen at t =-24C. Then wide excision of a tumour nidus follows. Next day, erythrocyte-enriched autoplasma is incubated with cisplatin - 100 mg, methotrexate - 50 mg, bleomycine - 15 mg in a thermostat for 30 min at t=37C and introduced drop-by-drop intravenously. It is combined with intradermal paratumour immunotherapy with Lifeferon pre-incubated from one of the portions of the defrosted plasma 10 ml within 10 days.

EFFECT: use of the invention allows reducing risk of recurrent tumour following surgical excision of a primary tumour due to enabled direct immunomodulator delivery to the tumour nidus and its prolonged local action.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is disclosed an application of complex iron (III) compounds with poly-maltha, hydrogenated dextrins or maltodextrin oxidation products for reparing an oral drug for iron deficiencies in patients suffering a chronic inflammatory intestinal disease, particularly Crohn's disease and nonspecific ulcerative colitis. When having been administered, the declared drugs have not invoked oxidative stress in contrast to iron sulphate therapy.

EFFECT: declared compounds are well tolerable, provide high compliance.

8 cl, 1 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose.

EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange.

5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing a microelement drug on the basis of an iron-dextrin complex. The method includes the following stages: mixed water-soluble iron (III) salt and one or more water-soluble salts containing other microelements, e.g., cobalt, copper, zinc, manganese and selenite, and low-molecular dextrin are neutralised before sedimentation of iron (III) hydroxide, alkalised to pH 9-11, heated up to complete resolution and neutralised with an acid. Then, membrane ultrafiltration procedure is used to purify the prepared colloidal iron-dextrin complex with microelement atoms deposited in a polymeric covalent lattice of iron (III) oxide, and to concentrate it.

EFFECT: method allows preparing high-effective high iron fixation polymicroelement drug ensuring the best effect in treating iron-deficient conditions and promoting immune system resistance.

3 cl, 2 dwg, 3 ex

Up!